1
|
Martin MG, Chidebe RCW, Nwaneri MO, Miller E, Okoye I, Esiaka DK, Olasinde TA, Durosinmi-Etti FA, Igbinoba F, Adegboyega BC, Adenjii A, Aruah CS, Orjiakor TC, Abubakar BM, Atuwo D, O'Connor T. Impact of 10-Day Fulbright Specialist Program and Project Pink Blue Education Sessions on Medical Oncology Knowledge Among Physicians Who Treat Cancer in Nigeria. J Cancer Educ 2023; 38:378-382. [PMID: 35838882 DOI: 10.1007/s13187-021-02130-y] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Accepted: 12/24/2021] [Indexed: 06/15/2023]
Abstract
Despite an estimated population of over 201 million and over 115,950 yearly diagnosed new cases of cancer, Nigeria does not have dedicated medical oncologists. Most oncology care is delivered through surgical and clinical oncologists, who are trained in both radiation and medical oncology and they number fewer than 50 in the country. With a limited number of oncology professionals, cancer patients in Nigeria experience poor health outcomes, with an estimated cancer mortality rate of 75,000 deaths per year. Participants from 15 Nigerian states were selected to attend the medical oncology training. Through the support of Fulbright Specialist Program and Project PINK BLUE, two of the authors delivered 10 days of lectures based on ASCO, ESMO, and NCCN guidelines. Mean scores of both the pre- and post-course tests as well as a 1-year follow-up test were compared using GraphPad Prism 7.0a by paired t-tests. Forty-four clinical oncologists were selected for participation. Twenty-five (57%) completed the pre- and post-course tests. Of the 25 that completed both tests, percentage of correct answers increased from 45 to 59% (2-sided p-value < 0.0001). Improvements were seen in attending doctors 45 to 59% (p = 0.0046) and resident doctors 45 to 59% (0.0007). Eleven doctors responded to the 1-year follow-up test. Although not statistically significant, a numerical pattern for the benefits was maintained 1 year after the program (45% pre-course versus 52% post-course correct answers, Fisher's exact, p = 0.4185). In the short term, the training improved medical oncology knowledge in Nigeria, regardless of the participant's carrier stage. Long-term benefits were not sustained in a small sample of participants, and continuing education strategies are necessary. Similar models may be employed across Africa.
Collapse
Affiliation(s)
- M G Martin
- West Cancer Center and Research Institute, Memphis, TN, USA.
- Fulbright Specialist Program, Washington, D.C., USA.
- West Cancer Center, 1588 Union Ave, Memphis, TN, 38104, USA.
- Birmingham City University, Birmingham, UK.
| | - R C W Chidebe
- Birmingham City University, Birmingham, UK
- Project PINK BLUE - Health & Psychological Trust Centre, Abuja, Nigeria
- National Cancer Control Programme, Federal Ministry of Health, Abuja, Nigeria
| | - M O Nwaneri
- Birmingham City University, Birmingham, UK
- Project PINK BLUE - Health & Psychological Trust Centre, Abuja, Nigeria
- University of Iowa Carver College of Medicine, Iowa City, IA, USA
| | - E Miller
- West Cancer Center and Research Institute, Memphis, TN, USA
- Birmingham City University, Birmingham, UK
| | - I Okoye
- Birmingham City University, Birmingham, UK
- Project PINK BLUE - Health & Psychological Trust Centre, Abuja, Nigeria
- University of Nigeria Teaching Hospital, Enugu, Nigeria
| | - D K Esiaka
- Birmingham City University, Birmingham, UK
- Union College, Schenectady, NY, USA
| | - T A Olasinde
- Birmingham City University, Birmingham, UK
- Ahmadu Bello University Teaching Hospital, Zaria, Nigeria
| | - F A Durosinmi-Etti
- Birmingham City University, Birmingham, UK
- Lagos University Teaching Hospital, Lagos, Nigeria
| | - F Igbinoba
- Birmingham City University, Birmingham, UK
- National Hospital, Abuja, Nigeria
| | - B C Adegboyega
- Birmingham City University, Birmingham, UK
- Lagos University Teaching Hospital, Lagos, Nigeria
| | - A Adenjii
- Birmingham City University, Birmingham, UK
- Lagos University Teaching Hospital, Lagos, Nigeria
| | - C S Aruah
- Birmingham City University, Birmingham, UK
- National Hospital, Abuja, Nigeria
- University of Abuja College of Medicine, Abuja, Nigeria
| | - T C Orjiakor
- Birmingham City University, Birmingham, UK
- University of Nigeria, Nsukka, Nigeria
| | - B M Abubakar
- Birmingham City University, Birmingham, UK
- National Hospital, Abuja, Nigeria
| | - D Atuwo
- Birmingham City University, Birmingham, UK
- National Cancer Control Programme, Federal Ministry of Health, Abuja, Nigeria
| | - T O'Connor
- Fulbright Specialist Program, Washington, D.C., USA
- Birmingham City University, Birmingham, UK
- Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA
| |
Collapse
|
2
|
Reardon DA, Idbaih A, Vieito M, Tabatabai G, Stradella A, Ghiringhelli F, Burger MC, Mildenberger I, González M, Hervieu A, Martin MG, Renovanz M, Touat M, Wen PY, Wick A, Gouttefangeas C, Maia A, Bonny C, Fagerberg J, Wick W. CTIM-17. EO2401 THERAPEUTIC VACCINE FOR PATIENTS WITH RECURRENT GLIOBLASTOMA: PHASE 1/2 ROSALIE STUDY (NCT04116658). Neuro Oncol 2022. [PMCID: PMC9660704 DOI: 10.1093/neuonc/noac209.249] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Abstract
EO2401 includes microbial-derived, synthetically produced HLA-A2 restricted peptides with molecular mimicry to antigens (IL13Rα2, BIRC5 and FOXM1) upregulated in glioblastoma, and the CD4 helper peptide UCP2. Patients with glioblastoma at first progression received EO2401 (300µg/peptide, q2weeks x4 then q4weeks), EO2401+nivolumab (3mg/kg q2weeks), or E02401+nivolumab+bevacizumab (10mg/kg q2weeks). Cohort-1 included EO2401x2 then EO2401+nivolumab. EO2401+nivolumab was evaluated in Cohort-2a, as adjuvant treatment in Cohort-2b, and as neoadjuvant/adjuvant treatment in Cohort-2c. Cohort-3 assessed EO2401+nivolumab+bevacizumab. Part 1 included 40 patients (Cohort-1/3, Cohort-2a/23, Cohort-2b/3, Cohort-3/11). Part 2 allowed low-dose-bevacizumab (5mg/kg q2weeks) for symptomatic edema and enrolled 38 patients (Cohort-1/18, Cohort-2a/15, Cohort-2b/3; and recruiting Cohort-2c/2 target 6, Cohort-3/0 target 15).Safety assessment of part 1 showed EO2401+nivolumab+/-bevacizumab to be well tolerated with EO2401 associated toxicity limited to local administration site reactions (48%; all grade 1-2). The nivolumab-/bevacizumab-toxicity was consistent with historical single-agent data. Strong CD8 T cell ELISPOT responses against the 3 vaccine peptides and cross-reactivity against targeted antigens was demonstrated in the majority of evaluable patients. Immune response was confirmed with tetramer staining of specific CD8 either ex vivo or after in vitro stimulation. For part 1, median progression-free survival (mPFS), and median survival (mOS) for EO2401+nivolumab (Cohorts-1/2/2b, n=29 median follow-up [mFU] 14.0 months) were 1.8 and 10.6 months. Patients on EO2401+nivolumab+bevacizumab (n = 11 mFU 9.6 m) had mPFS 5.5 months and 9 patients alive 7-12.4 months. Objective Response Rate/Disease Control Rate for EO2401+nivolumab and EO2401+nivolumab+bevacizumab was 10%/34% and 55%/82%.Median treatment duration for Cohort-2a part 1 was 6.1 weeks (1/23 on treatment), while it was 10.0 weeks (8/15 on treatment) for Cohort-2a part 2. Overall, in part 2, 36% received low-dose-bevacizumab.EO2401 generated strong immune responses and was well tolerated. Addition of standard bevacizumab to EO2401+nivolumab improved PFS and tumor response. Symptom driven low-dose-bevacizumab supported longer treatment durations. Outcome of study part 2 will be presented.
Collapse
Affiliation(s)
| | - Ahmed Idbaih
- Sorbonne Université, AP-HP, ICM, Hôpital Universitaire La Pitié-Salpêtrière , Paris , France
| | - Maria Vieito
- Vall d’Hebron Institute of Oncology (VHIO) , Barcelona , Spain
| | - Ghazaleh Tabatabai
- Department of Neurology & Interdisciplinary Neuro-Oncology, University Hospital Tübingen, Hertie Institute for Clinical Brain Research , Tübingen , Germany
| | - Agostina Stradella
- Institut Catala D'Oncologia - Hospital Duran i Reynals , Barcelona , Spain
| | | | - Michael C Burger
- Universitätsklinikum Frankfurt Goethe-Universität , Frankfurt , Germany
| | - Iris Mildenberger
- Department of Neurology, Medical Faculty Mannheim, University of Heidelberg , Mannheim , Germany
| | | | | | - Marta Gil Martin
- Institut Catala D'Oncologia - Hospital Duran i Reynals , Barcelona , Spain
| | - Mirjam Renovanz
- Department of Neurology & Interdisciplinary Neuro-Oncology, University Hospital Tübingen, Hertie Institute for Clinical Brain Research , Tübingen , Germany
| | - Mehdi Touat
- Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix , Service de Neurologie 2-Mazarin, F-75013, Paris , France
| | | | - Antje Wick
- Department of Neurology, University Hospital Heidelberg, and Clinical Cooperation Unit Neuro-Oncology, German Consortium for Translational Cancer Research (DKTK) and German Cancer Research Center (DKFZ). , Heidelberg , Germany
| | | | - Ana Maia
- Department of Immunology, Eberhard-Karls-University , Tübingen , Germany
| | | | | | - Wolfgang Wick
- Neurology Clinic and National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg , Baden-Wurttemberg , Germany
| |
Collapse
|
3
|
Owonikoko TK, Papadopoulos KP, Johnson ML, Gil Martin M, Moreno V, Salama AK, Calvo E, Yee NS, Safran H, González-Martín A, Aljumaily R, Mahadevan D, Niu J, Mohan KK, Li J, Stankevich E, Lowy I, Fury MG, Babiker HM. Phase 1 study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Final efficacy and safety data. J Clin Oncol 2018. [DOI: 10.1200/jco.2018.36.15_suppl.9557] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | | | | | - Marta Gil Martin
- Institut Català D'Oncologia, L’Hospitalet de Llobregat, Barcelona, Spain
| | - Victor Moreno
- START Madrid-FJD, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | | | - Emiliano Calvo
- START Madrid, Centro Integral Oncológico Clara Campal, Madrid, Spain
| | - Nelson S Yee
- Hematology/Oncology Division and Penn State Hershey Cancer Institute, Hershey, PA
| | | | | | | | | | - Jiaxin Niu
- Banner MD Anderson Cancer Center, Gilbert, AZ
| | | | - Jingjin Li
- Regeneron Pharmaceuticals Inc., Basking Ridge, NJ
| | | | - Israel Lowy
- Regeneron Pharmaceuticals Inc., Tarrytown, NY
| | | | | |
Collapse
|
4
|
Saura C, Thistlethwaite F, Banerji U, Lord S, Moreno V, MacPherson I, Boni V, Rolfo CD, de Vries EG, Van Herpen CM, Rottey S, Geenen JJ, Eskens F, Gil Martin M, Mommers E, Koper NP, Mulder R, Aftimos PG. A phase I expansion cohorts study of SYD985 in heavily pretreated patients with HER2-positive or HER2-low metastatic breast cancer. J Clin Oncol 2018. [DOI: 10.1200/jco.2018.36.15_suppl.1014] [Citation(s) in RCA: 31] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Cristina Saura
- Medical Oncology Department, Breast Cancer Group, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
| | - Fiona Thistlethwaite
- The Christie NHS Foundation Trust and University of Manchester, Manchester, United Kingdom
| | - Udai Banerji
- The Institute of Cancer Research and The Royal Marsden Hospital, London, United Kingdom
| | - Simon Lord
- Early Phase Clinical Trials Unit, Oxford University NHS Trust, Oxford, United Kingdom
| | - Victor Moreno
- START Madrid-FJD, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | | | | | | | | | | | - Sylvie Rottey
- Ghent University Hospital, Heymans Institute of Pharmacology, Ghent, Belgium
| | - Jill J.J. Geenen
- Netherlands Cancer Institute, department of molecular pathology, Amsterdam, Netherlands
| | - Ferry Eskens
- Erasmus MC Cancer Institute, Rotterdam, Netherlands
| | - Marta Gil Martin
- Institut Català D'Oncologia, L’Hospitalet de Llobregat, Barcelona, Spain
| | | | | | - Roel Mulder
- Synthon Biopharmaceuticals BV, Nijmegen, Netherlands
| | - Philippe Georges Aftimos
- Medical Oncology Clinic, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
| |
Collapse
|
5
|
Pérez-Montoyo H, Yeste-Velasco M, Solé-Sánchez S, Bragado P, Colàs-Ortega E, Eritja N, Lopez-Plana A, Fernandez-Nogueira P, Muñoz-Guardiola P, Megías-Roda E, Moiola C, Felip I, Nadal-Alforja E, Gil Martin M, Romeo M, Moran T, Gil-Moreno A, Matias-Guiu X, Domenech C, Lizcano JM. Development of TRIB3 as a novel preclinical and clinical pharmacodynamic biomarker for ABTL0812. J Clin Oncol 2018. [DOI: 10.1200/jco.2018.36.15_suppl.e14556] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | | | | | - Paloma Bragado
- Molecular and Translational Oncology Laboratory. Institut d'investigacions Biomèdiques August Pi i Sunyer (IDIBAPS). Clinic Barcelona Hospital Universitari, Barcelona, Spain
| | - Eva Colàs-Ortega
- Biomedical Research Group in Gynecology, Vall Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
| | - Nuria Eritja
- Pathological Oncology Group and Pathology Department, CIBERONC, Lleida Biomedical Research Center (IRBLleida), Universitary Hospital Arnau de Vilanova (HUAV), Lleida, Spain
| | - Anna Lopez-Plana
- Molecular and Translational Oncology Laboratory. Institut d'investigacions Biomèdiques August Pi i Sunyer (IDIBAPS). Clinic Barcelona Hospital Universitari, Barcelona, Spain
| | - Patricia Fernandez-Nogueira
- Molecular and Translational Oncology Laboratory. Institut d'investigacions Biomèdiques August Pi i Sunyer (IDIBAPS). Clinic Barcelona Hospital Universitari, Barcelona, Spain
| | | | | | - Cristian Moiola
- Biomedical Research Group in Gynecology, Vall Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
| | - Isidre Felip
- Pathological Oncology Group and Pathology Department, Lleida Biomedical Research Center (IRBLleida), Universitary Hospital Arnau de Vilanova (HUAV), Lleida, Spain
| | | | - Marta Gil Martin
- Institut Català D'Oncologia, L’Hospitalet de Llobregat, Barcelona, Spain
| | - Margarita Romeo
- Medical Oncology Department, Catalan Institute of Oncology- IDIBGi, Badalona, Spain
| | - Teresa Moran
- Medical Oncology Department. Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain
| | - Antonio Gil-Moreno
- Biomedical Research Group in Gynecology, Vall Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
| | - Xavier Matias-Guiu
- Pathological Oncology Group and Pathology Department, CIBERONC, Lleida Biomedical Research Center (IRBLleida), Universitary Hospital Arnau de Vilanova (HUAV), Lleida, Spain
| | - Carles Domenech
- Ability Pharmaceuticals, SL, Cerdanyola Del Vallès, Barcelona, Spain
| | - Jose M Lizcano
- Institut de Neurociencies, Universitat Autonoma de Barcelona, Bellaterra, Barcelona, Spain
| |
Collapse
|
6
|
Moreno Garcia V, Calvo E, Olmedo Garcia ME, Gil Martin M, Aljumaily R, Papadopoulos KP, Rosen LS, Rietschel P, Mohan KK, Li J, Stankevich E, Rowlands T, Feng M, Fury MG. Tolerability and antitumor activity of cemiplimab, a human monoclonal anti-PD-1, in patients with non-small cell lung cancer (NSCLC): Interim data from phase 1 dose escalation and NSCLC Expansion Cohort. J Clin Oncol 2018. [DOI: 10.1200/jco.2018.36.15_suppl.e21057] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | - Emiliano Calvo
- START Madrid, Centro Integral Oncológico Clara Campal, Madrid, Spain
| | | | - Marta Gil Martin
- Institut Català D'Oncologia, L’Hospitalet de Llobregat, Barcelona, Spain
| | | | | | - Lee S. Rosen
- UCLA Division of Hematology-Oncology, Los Angeles, CA
| | | | | | - Jingjin Li
- Regeneron Pharmaceuticals Inc., Basking Ridge, NJ
| | | | | | - Minjie Feng
- Regeneron Pharmaceuticals Inc., Basking Ridge, NJ
| | | |
Collapse
|
7
|
Papadopoulos KP, Owonikoko TK, Johnson M, Brana I, Gil Martin M, Perez RP, Moreno V, Salama AK, Calvo E, Yee NS, Safran H, Gonzalez Martin A, Aljumaily R, Mahadevan D, Mohan KK, Li J, Stankevich E, Lowy I, Fury MG, Homsi J. Cemiplimab (REGN2810): A fully human anti-PD-1 monoclonal antibody for patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC)—Initial safety and efficacy from expansion cohorts (ECs) of phase I study. J Clin Oncol 2018. [DOI: 10.1200/jco.2018.36.5_suppl.195] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
195 Background: There is no established standard of care for unresectable locally advanced or metastatic CSCC. UV-induced DNA damage causes hypermutation in most CSCCs. Therefore, these tumors may be responsive to PD-1 checkpoint blockade. In the dose escalation portion of the phase 1 study of cemiplimab (REGN2810), a durable (19 + months) radiologic complete response was observed in a patient (pt) with metastatic CSCC (ASCO 2015, #3024). Methods: ECs enrolled pts with distantly metastatic (EC 7) and locally advanced (EC 8) CSCC. All patients received cemiplimab 3 mg/kg by intravenous infusion over 30 minutes every 2 weeks for up to 48 weeks. Research biopsies were performed at baseline and Day 29 (and at progression, if possible). Tumor measurements were performed every 8 weeks according to RECIST 1.1 to determine overall response rate (ORR). Data cutoff date was 31 Jan 2017. Results: 26 pts were enrolled (10 in EC 7 and 16 in EC 8): median age, 72.5 y (range, 56–88y); median PS 1 (range, 0–1); 21M:5F; median number of prior systemic therapy regimens, 1 (range, 0–2). Median exposure to cemiplimab was 7 doses (range, 1–22). The most common treatment-related adverse event of any grade was fatigue (19.2%). Each of the following ≥ Grade 3 related AEs occurred once: AST elevation, ALT elevation, arthralgia, and rash. ORR (PR + CR, including unconfirmed) and disease control rate (ORR+SD) were 52% (12/23; 4uPR, 5 PR, 2CR, 1 uCR) and 70% (16/23, including 4SD), respectively. Three patients are not yet evaluable. Median PFS and OS have not been reached, and only one patient has experienced PD during cemiplimab treatment after initial response. Correlative studies are in process, including PD-L1 status and whole exome tumor DNA sequencing. Conclusions: Cemiplimab is well tolerated and produces antitumor activity in patients with advanced CSCC. A pivotal trial of cemiplimab for patients with advanced CSCC is enrolling patients. Clinical trial information: NCT02383212.
Collapse
Affiliation(s)
| | | | | | - Irene Brana
- Medical Oncology Department, Vall d’Hebron University Hospital, Barcelona, Spain
| | - Marta Gil Martin
- Institut Català D'Oncologia, L’Hospitalet de Llobregat, Barcelona, Spain
| | | | - Victor Moreno
- START Madrid-FJD, Fundación Jiménez Díaz, Madrid, Spain
| | | | - Emiliano Calvo
- START Madrid, Centro Integral Oncológico Clara Campal, Madrid, Spain
| | - Nelson S Yee
- Hematology/Oncology Division and Penn State Hershey Cancer Institute, Hershey, PA
| | | | | | - Raid Aljumaily
- Stephenson Cancer Center/Oklahoma University Medical Center, Oklahoma City, OK
| | | | | | - Jingjin Li
- Regeneron Pharmaceuticals, Inc., Basking Ridge, NJ
| | | | - Israel Lowy
- Regeneron Pharmaceuticals Inc., Tarrytown, NY
| | | | - Jade Homsi
- University of Texas Southwestern Medical Center, Dallas, TX
| |
Collapse
|
8
|
Dworkin JP, Adelman LA, Ajluni T, Andronikov AV, Aponte JC, Bartels AE, Beshore E, Bierhaus EB, Brucato JR, Bryan BH, Burton AS, Callahan MP, Castro-Wallace SL, Clark BC, Clemett SJ, Connolly HC, Cutlip WE, Daly SM, Elliott VE, Elsila JE, Enos HL, Everett DF, Franchi IA, Glavin DP, Graham HV, Hendershot JE, Harris JW, Hill SL, Hildebrand AR, Jayne GO, Jenkens RW, Johnson KS, Kirsch JS, Lauretta DS, Lewis AS, Loiacono JJ, Lorentson CC, Marshall JR, Martin MG, Matthias LL, McLain HL, Messenger SR, Mink RG, Moore JL, Nakamura-Messenger K, Nuth JA, Owens CV, Parish CL, Perkins BD, Pryzby MS, Reigle CA, Righter K, Rizk B, Russell JF, Sandford SA, Schepis JP, Songer J, Sovinski MF, Stahl SE, Thomas-Keprta K, Vellinga JM, Walker MS. OSIRIS-REx Contamination Control Strategy and Implementation. Space Sci Rev 2018; 214:19. [PMID: 30713357 PMCID: PMC6350808 DOI: 10.1007/s11214-017-0439-4] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/10/2023]
Abstract
OSIRIS-REx will return pristine samples of carbonaceous asteroid Bennu. This article describes how pristine was defined based on expectations of Bennu and on a realistic understanding of what is achievable with a constrained schedule and budget, and how that definition flowed to requirements and implementation. To return a pristine sample, the OSIRIS-REx spacecraft sampling hardware was maintained at level 100 A/2 and <180 ng/cm2 of amino acids and hydrazine on the sampler head through precision cleaning, control of materials, and vigilance. Contamination is further characterized via witness material exposed to the spacecraft assembly and testing environment as well as in space. This characterization provided knowledge of the expected background and will be used in conjunction with archived spacecraft components for comparison with the samples when they are delivered to Earth for analysis. Most of all, the cleanliness of the OSIRIS-REx spacecraft was achieved through communication among scientists, engineers, managers, and technicians.
Collapse
Affiliation(s)
- J P Dworkin
- NASA Goddard Space Flight Center, Greenbelt, MD, USA
| | - L A Adelman
- NASA Goddard Space Flight Center, Greenbelt, MD, USA
- Arctic Slope Research Corporation, Beltsville, MD USA
| | - T Ajluni
- NASA Goddard Space Flight Center, Greenbelt, MD, USA
- Arctic Slope Research Corporation, Beltsville, MD USA
| | | | - J C Aponte
- NASA Goddard Space Flight Center, Greenbelt, MD, USA
- Catholic University of America, Washington, DC, USA
| | - A E Bartels
- NASA Goddard Space Flight Center, Greenbelt, MD, USA
| | - E Beshore
- Lunar and Planetary Laboratory, University of Arizona, Tucson, AZ, USA
| | - E B Bierhaus
- Lockheed Martin Space Systems, Littleton, CO, USA
| | - J R Brucato
- INAF Astrophysical Observatory of Arcetri, Florence, Italy
| | - B H Bryan
- Lockheed Martin Space Systems, Littleton, CO, USA
| | - A S Burton
- NASA Johnson Space Center, Houston, TX, USA
| | | | | | - B C Clark
- Space Science Institute, Boulder, CO, USA
| | - S J Clemett
- NASA Johnson Space Center, Houston, TX, USA
- Jacobs Technology, Tullahoma, TN, USA
| | | | - W E Cutlip
- NASA Goddard Space Flight Center, Greenbelt, MD, USA
| | - S M Daly
- NASA Kennedy Space Center, Titusville, FL, USA
| | - V E Elliott
- NASA Goddard Space Flight Center, Greenbelt, MD, USA
| | - J E Elsila
- NASA Goddard Space Flight Center, Greenbelt, MD, USA
| | - H L Enos
- Lunar and Planetary Laboratory, University of Arizona, Tucson, AZ, USA
| | - D F Everett
- NASA Goddard Space Flight Center, Greenbelt, MD, USA
| | | | - D P Glavin
- NASA Goddard Space Flight Center, Greenbelt, MD, USA
| | - H V Graham
- NASA Goddard Space Flight Center, Greenbelt, MD, USA
- University of Maryland, College Park, MD, USA
| | - J E Hendershot
- NASA Goddard Space Flight Center, Greenbelt, MD, USA
- Ball Aerospace, Boulder, CO, USA
| | - J W Harris
- Lockheed Martin Space Systems, Littleton, CO, USA
| | - S L Hill
- Jacobs Technology, Tullahoma, TN, USA
- NASA Kennedy Space Center, Titusville, FL, USA
| | | | - G O Jayne
- NASA Goddard Space Flight Center, Greenbelt, MD, USA
- Arctic Slope Research Corporation, Beltsville, MD USA
| | - R W Jenkens
- NASA Goddard Space Flight Center, Greenbelt, MD, USA
| | - K S Johnson
- Lockheed Martin Space Systems, Littleton, CO, USA
| | - J S Kirsch
- Jacobs Technology, Tullahoma, TN, USA
- NASA Kennedy Space Center, Titusville, FL, USA
| | - D S Lauretta
- Lunar and Planetary Laboratory, University of Arizona, Tucson, AZ, USA
| | - A S Lewis
- NASA Goddard Space Flight Center, Greenbelt, MD, USA
| | - J J Loiacono
- NASA Goddard Space Flight Center, Greenbelt, MD, USA
| | - C C Lorentson
- NASA Goddard Space Flight Center, Greenbelt, MD, USA
| | | | - M G Martin
- NASA Goddard Space Flight Center, Greenbelt, MD, USA
- Catholic University of America, Washington, DC, USA
| | - L L Matthias
- NASA Kennedy Space Center, Titusville, FL, USA
- Analex, Titusville, FL, USA
| | - H L McLain
- NASA Goddard Space Flight Center, Greenbelt, MD, USA
- Catholic University of America, Washington, DC, USA
| | | | - R G Mink
- NASA Goddard Space Flight Center, Greenbelt, MD, USA
| | - J L Moore
- Lockheed Martin Space Systems, Littleton, CO, USA
| | | | - J A Nuth
- NASA Goddard Space Flight Center, Greenbelt, MD, USA
| | - C V Owens
- NASA Kennedy Space Center, Titusville, FL, USA
| | - C L Parish
- Lockheed Martin Space Systems, Littleton, CO, USA
| | - B D Perkins
- NASA Kennedy Space Center, Titusville, FL, USA
| | - M S Pryzby
- NASA Goddard Space Flight Center, Greenbelt, MD, USA
- ATA Aerospace, Albuquerque, NM, USA
| | - C A Reigle
- Lockheed Martin Space Systems, Littleton, CO, USA
| | - K Righter
- NASA Johnson Space Center, Houston, TX, USA
| | - B Rizk
- Lunar and Planetary Laboratory, University of Arizona, Tucson, AZ, USA
| | - J F Russell
- Lockheed Martin Space Systems, Littleton, CO, USA
| | - S A Sandford
- NASA Ames Research Center, Moffett Field, CA, USA
| | - J P Schepis
- NASA Goddard Space Flight Center, Greenbelt, MD, USA
| | - J Songer
- Lockheed Martin Space Systems, Littleton, CO, USA
| | - M F Sovinski
- NASA Goddard Space Flight Center, Greenbelt, MD, USA
| | - S E Stahl
- NASA Johnson Space Center, Houston, TX, USA
- JES Tech., Houston, TX, USA
| | - K Thomas-Keprta
- NASA Johnson Space Center, Houston, TX, USA
- Jacobs Technology, Tullahoma, TN, USA
| | - J M Vellinga
- Lockheed Martin Space Systems, Littleton, CO, USA
| | - M S Walker
- NASA Goddard Space Flight Center, Greenbelt, MD, USA
| |
Collapse
|
9
|
Abstract
PCSK1, encoding prohormone convertase 1/3 (PC1/3), was one of the first genes linked to monogenic early-onset obesity. PC1/3 is a protease involved in the biosynthetic processing of a variety of neuropeptides and prohormones in endocrine tissues. PC1/3 activity is essential for the activating cleavage of many peptide hormone precursors implicated in the regulation of food ingestion, glucose homeostasis, and energy homeostasis, for example, proopiomelanocortin, proinsulin, proglucagon, and proghrelin. A large number of genome-wide association studies in a variety of different populations have now firmly established a link between three PCSK1 polymorphisms frequent in the population and increased risk of obesity. Human subjects with PC1/3 deficiency, a rare autosomal-recessive disorder caused by the presence of loss-of-function mutations in both alleles, are obese and display a complex set of endocrinopathies. Increasing numbers of genetic diagnoses of infants with persistent diarrhea has recently led to the finding of many novel PCSK1 mutations. PCSK1-deficient infants experience severe intestinal malabsorption during the first years of life, requiring controlled nutrition; these children then become hyperphagic, with associated obesity. The biochemical characterization of novel loss-of-function PCSK1 mutations has resulted in the discovery of new pathological mechanisms affecting the cell biology of the endocrine cell beyond simple loss of enzyme activity, for example, dominant-negative effects of certain mutants on wild-type PC1/3 protein, and activation of the cellular unfolded protein response by endoplasmic reticulum-retained mutants. A better understanding of these molecular and cellular pathologies may illuminate possible treatments for the complex endocrinopathy of PCSK1 deficiency, including obesity.
Collapse
Affiliation(s)
- B Ramos-Molina
- Department of Human Genetics, KU Leuven, Leuven, Belgium
| | - M G Martin
- Department of Pediatrics, Division of Gastroenterology and Nutrition, Mattel Children's Hospital and the David Geffen School of Medicine, Los Angeles, CA, United States of America
| | - I Lindberg
- Department of Anatomy and Neurobiology, University of Maryland, Baltimore, MD, United States of America.
| |
Collapse
|
10
|
Freissinet C, Glavin DP, Mahaffy PR, Miller KE, Eigenbrode JL, Summons RE, Brunner AE, Buch A, Szopa C, Archer PD, Franz HB, Atreya SK, Brinckerhoff WB, Cabane M, Coll P, Conrad PG, Des Marais DJ, Dworkin JP, Fairén AG, François P, Grotzinger JP, Kashyap S, ten Kate IL, Leshin LA, Malespin CA, Martin MG, Martin-Torres FJ, McAdam AC, Ming DW, Navarro-González R, Pavlov AA, Prats BD, Squyres SW, Steele A, Stern JC, Sumner DY, Sutter B, Zorzano MP. Organic molecules in the Sheepbed Mudstone, Gale Crater, Mars. J Geophys Res Planets 2015; 120:495-514. [PMID: 26690960 PMCID: PMC4672966 DOI: 10.1002/2014je004737] [Citation(s) in RCA: 149] [Impact Index Per Article: 16.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/03/2014] [Revised: 01/12/2015] [Accepted: 02/13/2015] [Indexed: 05/04/2023]
Abstract
UNLABELLED The Sample Analysis at Mars (SAM) instrument on board the Mars Science Laboratory Curiosity rover is designed to conduct inorganic and organic chemical analyses of the atmosphere and the surface regolith and rocks to help evaluate the past and present habitability potential of Mars at Gale Crater. Central to this task is the development of an inventory of any organic molecules present to elucidate processes associated with their origin, diagenesis, concentration, and long-term preservation. This will guide the future search for biosignatures. Here we report the definitive identification of chlorobenzene (150-300 parts per billion by weight (ppbw)) and C2 to C4 dichloroalkanes (up to 70 ppbw) with the SAM gas chromatograph mass spectrometer (GCMS) and detection of chlorobenzene in the direct evolved gas analysis (EGA) mode, in multiple portions of the fines from the Cumberland drill hole in the Sheepbed mudstone at Yellowknife Bay. When combined with GCMS and EGA data from multiple scooped and drilled samples, blank runs, and supporting laboratory analog studies, the elevated levels of chlorobenzene and the dichloroalkanes cannot be solely explained by instrument background sources known to be present in SAM. We conclude that these chlorinated hydrocarbons are the reaction products of Martian chlorine and organic carbon derived from Martian sources (e.g., igneous, hydrothermal, atmospheric, or biological) or exogenous sources such as meteorites, comets, or interplanetary dust particles. KEY POINTS First in situ evidence of nonterrestrial organics in Martian surface sediments Chlorinated hydrocarbons identified in the Sheepbed mudstone by SAM Organics preserved in sample exposed to ionizing radiation and oxidative condition.
Collapse
Affiliation(s)
- C Freissinet
- Solar System Exploration Division, NASA Goddard Space Flight CenterGreenbelt, Maryland, USA
- NASA Postdoctoral Program, Oak Ridge Associated UniversitiesOak Ridge, Tennessee, USA
- Correspondence to:
C. Freissinet and P. R. Mahaffy,, ,
| | - D P Glavin
- Solar System Exploration Division, NASA Goddard Space Flight CenterGreenbelt, Maryland, USA
| | - P R Mahaffy
- Solar System Exploration Division, NASA Goddard Space Flight CenterGreenbelt, Maryland, USA
- Correspondence to:
C. Freissinet and P. R. Mahaffy,, ,
| | - K E Miller
- Department of Earth, Atmospheric and Planetary Sciences, Massachusetts Institute of TechnologyCambridge, Massachusetts, USA
| | - J L Eigenbrode
- Solar System Exploration Division, NASA Goddard Space Flight CenterGreenbelt, Maryland, USA
| | - R E Summons
- Department of Earth, Atmospheric and Planetary Sciences, Massachusetts Institute of TechnologyCambridge, Massachusetts, USA
| | - A E Brunner
- Solar System Exploration Division, NASA Goddard Space Flight CenterGreenbelt, Maryland, USA
- Center for Research and Exploration in Space Science & Technology, University of MarylandCollege Park, Maryland, USA
| | - A Buch
- Laboratoire de Génie des Procédés et Matériaux, Ecole Centrale ParisChâtenay-Malabry, France
| | - C Szopa
- Laboratoire Atmosphères, Milieux, Observations Spatiales, Pierre and Marie Curie University, Université de Versailles Saint-Quentin-en-Yvelines, and CNRSParis, France
| | - P D Archer
- Jacobs, NASA Johnson Space CenterHouston, Texas, USA
| | - H B Franz
- Solar System Exploration Division, NASA Goddard Space Flight CenterGreenbelt, Maryland, USA
- Center for Research and Exploration in Space Science & Technology, University of Maryland, Baltimore CountyBaltimore, Maryland, USA
| | - S K Atreya
- Department of Atmospheric, Oceanic and Space Sciences, University of MichiganAnn Arbor, Michigan, USA
| | - W B Brinckerhoff
- Solar System Exploration Division, NASA Goddard Space Flight CenterGreenbelt, Maryland, USA
| | - M Cabane
- Laboratoire Atmosphères, Milieux, Observations Spatiales, Pierre and Marie Curie University, Université de Versailles Saint-Quentin-en-Yvelines, and CNRSParis, France
| | - P Coll
- Laboratoire Interuniversitaire des Systèmes Atmosphériques, Université Paris-Est Créteil, Paris VII–Denis Diderot University, and CNRSCréteil, France
| | - P G Conrad
- Solar System Exploration Division, NASA Goddard Space Flight CenterGreenbelt, Maryland, USA
| | - D J Des Marais
- Exobiology Branch, NASA Ames Research CenterMoffett Field, California, USA
| | - J P Dworkin
- Solar System Exploration Division, NASA Goddard Space Flight CenterGreenbelt, Maryland, USA
| | - A G Fairén
- Department of Astronomy, Cornell UniversityIthaca, New York, USA
- Centro de Astrobiología, INTA-CSICMadrid, Spain
| | - P François
- Department of Atmospheric, Oceanic and Space Sciences, University of MichiganAnn Arbor, Michigan, USA
| | - J P Grotzinger
- Division of Geological and Planetary Sciences, California Institute of TechnologyPasadena, California, USA
| | - S Kashyap
- Solar System Exploration Division, NASA Goddard Space Flight CenterGreenbelt, Maryland, USA
- Center for Research and Exploration in Space Science & Technology, University of Maryland, Baltimore CountyBaltimore, Maryland, USA
| | - I L ten Kate
- Earth Sciences Department, Utrecht UniversityUtrecht, Netherlands
| | - L A Leshin
- Department of Earth and Environmental Sciences and School of Science, Rensselaer Polytechnic InstituteTroy, New York, USA
| | - C A Malespin
- Solar System Exploration Division, NASA Goddard Space Flight CenterGreenbelt, Maryland, USA
- Goddard Earth Sciences and Technologies and Research, Universities Space Research AssociationColumbia, Maryland, USA
| | - M G Martin
- Solar System Exploration Division, NASA Goddard Space Flight CenterGreenbelt, Maryland, USA
- Department of Chemistry, Catholic University of AmericaWashington, District of Columbia, USA
| | - F J Martin-Torres
- Instituto Andaluz de Ciencias de la Tierra (CSIC-UGR)Granada, Spain
- Division of Space Technology, Department of Computer Science, Electrical and Space Engineering, Luleå University of TechnologyKiruna, Sweden
| | - A C McAdam
- Solar System Exploration Division, NASA Goddard Space Flight CenterGreenbelt, Maryland, USA
| | - D W Ming
- Astromaterials Research and Exploration Science Directorate, NASA Johnson Space CenterHouston, Texas, USA
| | - R Navarro-González
- Instituto de Ciencias Nucleares, Universidad Nacional Autónoma de México, Ciudad UniversitariaMéxico City, Mexico
| | - A A Pavlov
- Solar System Exploration Division, NASA Goddard Space Flight CenterGreenbelt, Maryland, USA
| | - B D Prats
- Solar System Exploration Division, NASA Goddard Space Flight CenterGreenbelt, Maryland, USA
| | - S W Squyres
- Department of Astronomy, Cornell UniversityIthaca, New York, USA
| | - A Steele
- Geophysical Laboratory, Carnegie Institution of WashingtonWashington, District of Columbia, USA
| | - J C Stern
- Solar System Exploration Division, NASA Goddard Space Flight CenterGreenbelt, Maryland, USA
| | - D Y Sumner
- Department of Earth and Planetary Sciences, University of CaliforniaDavis, California, USA
| | - B Sutter
- Jacobs, NASA Johnson Space CenterHouston, Texas, USA
| | - M-P Zorzano
- Centro de Astrobiologia (INTA-CSIC)Madrid, Spain
| |
Collapse
|
11
|
Freissinet C, Glavin DP, Mahaffy PR, Miller KE, Eigenbrode JL, Summons RE, Brunner AE, Buch A, Szopa C, Archer PD, Franz HB, Atreya SK, Brinckerhoff WB, Cabane M, Coll P, Conrad PG, Des Marais DJ, Dworkin JP, Fairén AG, François P, Grotzinger JP, Kashyap S, Ten Kate IL, Leshin LA, Malespin CA, Martin MG, Martin-Torres FJ, McAdam AC, Ming DW, Navarro-González R, Pavlov AA, Prats BD, Squyres SW, Steele A, Stern JC, Sumner DY, Sutter B, Zorzano MP. Organic molecules in the Sheepbed Mudstone, Gale Crater, Mars. J Geophys Res Planets 2015; 120:495-514. [PMID: 26690960 DOI: 10.1002/2015je004884.received] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Received: 10/03/2014] [Revised: 01/12/2015] [Accepted: 02/13/2015] [Indexed: 05/25/2023]
Abstract
UNLABELLED The Sample Analysis at Mars (SAM) instrument on board the Mars Science Laboratory Curiosity rover is designed to conduct inorganic and organic chemical analyses of the atmosphere and the surface regolith and rocks to help evaluate the past and present habitability potential of Mars at Gale Crater. Central to this task is the development of an inventory of any organic molecules present to elucidate processes associated with their origin, diagenesis, concentration, and long-term preservation. This will guide the future search for biosignatures. Here we report the definitive identification of chlorobenzene (150-300 parts per billion by weight (ppbw)) and C2 to C4 dichloroalkanes (up to 70 ppbw) with the SAM gas chromatograph mass spectrometer (GCMS) and detection of chlorobenzene in the direct evolved gas analysis (EGA) mode, in multiple portions of the fines from the Cumberland drill hole in the Sheepbed mudstone at Yellowknife Bay. When combined with GCMS and EGA data from multiple scooped and drilled samples, blank runs, and supporting laboratory analog studies, the elevated levels of chlorobenzene and the dichloroalkanes cannot be solely explained by instrument background sources known to be present in SAM. We conclude that these chlorinated hydrocarbons are the reaction products of Martian chlorine and organic carbon derived from Martian sources (e.g., igneous, hydrothermal, atmospheric, or biological) or exogenous sources such as meteorites, comets, or interplanetary dust particles. KEY POINTS First in situ evidence of nonterrestrial organics in Martian surface sediments Chlorinated hydrocarbons identified in the Sheepbed mudstone by SAM Organics preserved in sample exposed to ionizing radiation and oxidative condition.
Collapse
Affiliation(s)
- C Freissinet
- Solar System Exploration Division, NASA Goddard Space Flight Center Greenbelt, Maryland, USA ; NASA Postdoctoral Program, Oak Ridge Associated Universities Oak Ridge, Tennessee, USA
| | - D P Glavin
- Solar System Exploration Division, NASA Goddard Space Flight Center Greenbelt, Maryland, USA
| | - P R Mahaffy
- Solar System Exploration Division, NASA Goddard Space Flight Center Greenbelt, Maryland, USA
| | - K E Miller
- Department of Earth, Atmospheric and Planetary Sciences, Massachusetts Institute of Technology Cambridge, Massachusetts, USA
| | - J L Eigenbrode
- Solar System Exploration Division, NASA Goddard Space Flight Center Greenbelt, Maryland, USA
| | - R E Summons
- Department of Earth, Atmospheric and Planetary Sciences, Massachusetts Institute of Technology Cambridge, Massachusetts, USA
| | - A E Brunner
- Solar System Exploration Division, NASA Goddard Space Flight Center Greenbelt, Maryland, USA ; Center for Research and Exploration in Space Science & Technology, University of Maryland College Park, Maryland, USA
| | - A Buch
- Laboratoire de Génie des Procédés et Matériaux, Ecole Centrale Paris Châtenay-Malabry, France
| | - C Szopa
- Laboratoire Atmosphères, Milieux, Observations Spatiales, Pierre and Marie Curie University, Université de Versailles Saint-Quentin-en-Yvelines, and CNRS Paris, France
| | - P D Archer
- Jacobs, NASA Johnson Space Center Houston, Texas, USA
| | - H B Franz
- Solar System Exploration Division, NASA Goddard Space Flight Center Greenbelt, Maryland, USA ; Center for Research and Exploration in Space Science & Technology, University of Maryland, Baltimore County Baltimore, Maryland, USA
| | - S K Atreya
- Department of Atmospheric, Oceanic and Space Sciences, University of Michigan Ann Arbor, Michigan, USA
| | - W B Brinckerhoff
- Solar System Exploration Division, NASA Goddard Space Flight Center Greenbelt, Maryland, USA
| | - M Cabane
- Laboratoire Atmosphères, Milieux, Observations Spatiales, Pierre and Marie Curie University, Université de Versailles Saint-Quentin-en-Yvelines, and CNRS Paris, France
| | - P Coll
- Laboratoire Interuniversitaire des Systèmes Atmosphériques, Université Paris-Est Créteil, Paris VII-Denis Diderot University, and CNRS Créteil, France
| | - P G Conrad
- Solar System Exploration Division, NASA Goddard Space Flight Center Greenbelt, Maryland, USA
| | - D J Des Marais
- Exobiology Branch, NASA Ames Research Center Moffett Field, California, USA
| | - J P Dworkin
- Solar System Exploration Division, NASA Goddard Space Flight Center Greenbelt, Maryland, USA
| | - A G Fairén
- Department of Astronomy, Cornell University Ithaca, New York, USA ; Centro de Astrobiología, INTA-CSIC Madrid, Spain
| | - P François
- Department of Atmospheric, Oceanic and Space Sciences, University of Michigan Ann Arbor, Michigan, USA
| | - J P Grotzinger
- Division of Geological and Planetary Sciences, California Institute of Technology Pasadena, California, USA
| | - S Kashyap
- Solar System Exploration Division, NASA Goddard Space Flight Center Greenbelt, Maryland, USA ; Center for Research and Exploration in Space Science & Technology, University of Maryland, Baltimore County Baltimore, Maryland, USA
| | - I L Ten Kate
- Earth Sciences Department, Utrecht University Utrecht, Netherlands
| | - L A Leshin
- Department of Earth and Environmental Sciences and School of Science, Rensselaer Polytechnic Institute Troy, New York, USA
| | - C A Malespin
- Solar System Exploration Division, NASA Goddard Space Flight Center Greenbelt, Maryland, USA ; Goddard Earth Sciences and Technologies and Research, Universities Space Research Association Columbia, Maryland, USA
| | - M G Martin
- Solar System Exploration Division, NASA Goddard Space Flight Center Greenbelt, Maryland, USA ; Department of Chemistry, Catholic University of America Washington, District of Columbia, USA
| | - F J Martin-Torres
- Instituto Andaluz de Ciencias de la Tierra (CSIC-UGR) Granada, Spain ; Division of Space Technology, Department of Computer Science, Electrical and Space Engineering, Luleå University of Technology Kiruna, Sweden
| | - A C McAdam
- Solar System Exploration Division, NASA Goddard Space Flight Center Greenbelt, Maryland, USA
| | - D W Ming
- Astromaterials Research and Exploration Science Directorate, NASA Johnson Space Center Houston, Texas, USA
| | - R Navarro-González
- Instituto de Ciencias Nucleares, Universidad Nacional Autónoma de México, Ciudad Universitaria México City, Mexico
| | - A A Pavlov
- Solar System Exploration Division, NASA Goddard Space Flight Center Greenbelt, Maryland, USA
| | - B D Prats
- Solar System Exploration Division, NASA Goddard Space Flight Center Greenbelt, Maryland, USA
| | - S W Squyres
- Department of Astronomy, Cornell University Ithaca, New York, USA
| | - A Steele
- Geophysical Laboratory, Carnegie Institution of Washington Washington, District of Columbia, USA
| | - J C Stern
- Solar System Exploration Division, NASA Goddard Space Flight Center Greenbelt, Maryland, USA
| | - D Y Sumner
- Department of Earth and Planetary Sciences, University of California Davis, California, USA
| | - B Sutter
- Jacobs, NASA Johnson Space Center Houston, Texas, USA
| | - M-P Zorzano
- Centro de Astrobiologia (INTA-CSIC) Madrid, Spain
| |
Collapse
|
12
|
Martin MG, Uy GL, Procknow E, Stockerl-Goldstein K, Cashen A, Westervelt P, Abboud CN, Augustin K, Luo J, DiPersio JF, Vij R. Allo-SCT conditioning for myelodysplastic syndrome and acute myeloid leukemia with clofarabine, cytarabine and ATG. Bone Marrow Transplant 2009; 44:13-7. [PMID: 19139740 DOI: 10.1038/bmt.2008.423] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
The application of myeloablative Allo-SCT is limited by its associated morbidity and mortality. Reduced-intensity conditioning regimens attempt to diminish these, but are associated with a higher risk of disease relapse. Given the evidence of activity of clofarabine and cytarabine in myelodysplastic syndrome/acute myeloid leukemia (MDS/AML), we explored a novel reduced-intensity conditioning regimen based on this backbone. Patients received clofarabine 40 mg/m(2) i.v. on days -6 to -2, cytarabine 1 g/m(2) i.v. on days -6 to -2 and anti-thymocyte globulin (ATG) 1 mg/kg on day -4 and 2.5 mg/kg x 2 days on days -3 and -2. Seven patients were enrolled. Their median age was 54 years; three were with MDS and four with AML. The median duration of neutropenia was 14 days and that of thrombocytopenia was 22 days. Toxicities included hand-foot syndrome (57% grade 2), elevated alanine aminotransferase (ALT) (57% grade 3), elevated aspartate aminotransferase (AST) (86% grade 3) and hyperbilirubinemia (29% grade 3-5). No acute GVHD was observed. Enrollment to the trial was halted after three of the first seven patients expired on days +15, +26 and +32. Three of the four surviving patients have relapsed with a median TTP of 152 days. This regimen was not sufficiently immunosuppressive to ensure engraftment, and was associated with substantial morbidity and mortality.
Collapse
Affiliation(s)
- M G Martin
- Section of Leukemia and Bone Marrow Transplantation, Division of Oncology, Washington University School of Medicine, Saint Louis, MO 63110, USA.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Venick RS, McDiarmid SV, Farmer DG, Gornbein J, Martin MG, Vargas JH, Ament ME, Busuttil RW. Rejection and steroid dependence: unique risk factors in the development of pediatric posttransplant de novo autoimmune hepatitis. Am J Transplant 2007; 7:955-63. [PMID: 17391135 DOI: 10.1111/j.1600-6143.2006.01717.x] [Citation(s) in RCA: 77] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Posttransplant de novo autoimmune hepatitis (d-AIH) is increasingly described as a long-term complication after pediatric liver transplantation (LT). d-AIH is characterized by graft dysfunction, the development of autoimmune antibodies and histologic evidence of hepatitis in liver transplant recipients without previous history of autoimmune liver disease. This study is a matched case-control, univariate analysis aimed at identifying risk factors for the development of d-AIH and evaluating response to treatment. From 1984 to 2003, 619 children received 788 LTs at a single center. Forty-one patients developed d-AIH and were matched with controls for year of LT, age at time of LT and diagnosis. The following variables were insignificant in the development of d-AIH: age, gender, race, initial diagnosis, ischemia time, graft type, Epstein-Barr virus and cytomegalovirus status, HLA typing and primary immunosuppression. Compared to controls, d-AIH patients were less likely to be on monotherapy immunosuppression or weaned off prednisone at the time of diagnosis. The d-AIH group relative to the controls had statistically significant greater numbers of rejection episodes. d-AIH was treated with prednisone and/or MMF in 39 of 41 patients and lead to significant improvements in liver function tests. Thirty-nine patients are alive at a mean of 4.0 years follow-up after diagnosis. Three have required retransplantation.
Collapse
Affiliation(s)
- R S Venick
- Department of Pediatrics, The David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
| | | | | | | | | | | | | | | |
Collapse
|
14
|
Izquierdo M, Dávila ME, Avila J, Ascolani H, Teodorescu CM, Martin MG, Franco N, Chrost J, Arranz A, Asensio MC. Epitaxy and magnetic properties of surfactant-mediated growth of bcc cobalt. Phys Rev Lett 2005; 94:187601. [PMID: 15904410 DOI: 10.1103/physrevlett.94.187601] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/10/2004] [Indexed: 05/02/2023]
Abstract
High resolution core level photoemission spectroscopy, photoelectron diffraction, and x-ray magnetic circular dicroism (XMCD) have been used to characterize the structural and magnetic properties of bcc-cobalt films grown on GaAs(110) substrates by using Sb as a surfactant. We have unambiguously disentangled the surfactant role played by the Sb which improves the crystallinity and reduces the lattice distortion of the metallic films as well as changes the interdiffusion process at the interface compared to the Co/GaAs(110) system. As a consequence of these combined effects, an improvement on the magnetic response of the grown Co thin films has been observed by XMCD measurements.
Collapse
Affiliation(s)
- M Izquierdo
- Synchrotron SOLEIL, L'Orme des Merisiers, Saint-Aubin, BP 48, 91192 Gif-sur-Yvette CEDEX, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Steinmetz BA, Martin MG, Roberts RL. Granulocyte-macrophage colony-stimulating factor for treating gastrostomy tube site healing in a child with glycogen storage disease type Ib. J Pediatr Gastroenterol Nutr 2001; 33:94-6. [PMID: 11479417 DOI: 10.1097/00005176-200107000-00019] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/10/2022]
Affiliation(s)
- B A Steinmetz
- Division of Pediatric Gastroenterology and Nutrition, Department of Pediatrics, University of California at Los Angeles, Los Angeles, CA 90095, U.S.A
| | | | | |
Collapse
|
16
|
Quiros-Tejeira RE, Ament ME, Heyman MB, Martin MG, Rosenthal P, Gornbein JA, McDiarmid SV, Vargas JH. Does liver transplantation affect growth pattern in Alagille syndrome? Liver Transpl 2000; 6:582-7. [PMID: 10980057 DOI: 10.1053/jlts.2000.9739] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Alagille syndrome (AGS) is frequently associated with growth failure, which has been attributed to concurrent congenital anomalies, cholestasis, and malabsorption and/or malnutrition. However, the underlying cause of the growth failure is not well understood. Our objective is to analyze the growth pattern in 26 patients with AGS and the possible effect that orthotopic liver transplantation (OLT) may have on this pattern. The standardized height, weight, and growth velocity of 26 pair-matched patients with AGS were compared. Thirteen patients underwent OLT. Repeated-measure ANOVA methods were used for the statistical analysis. The overall mean standardized height (z score) was -2.92 in the OLT group versus -1.88 in the non-OLT group (P =.03). The overall mean standardized weight was -1. 21 in the non-OLT group and -1.67 in the OLT group (P =.23). In 15 patients, birth weight was 2.82 +/- 0.4 kg, for a mean standardized weight of -0.95, and weight at diagnosis was 4.53 +/- 2.12 kg, for a mean standardized weight of -1.56. Bone age was delayed in the 9 patients who underwent bone-age analysis. Growth hormone therapy administered to 2 patients did not improve growth. Patients with AGS had growth failure secondary to other factors in addition to liver disease. Growth failure beginning in the prenatal period supports a genetic basis for this feature. Growth improvement up to normal levels should not be expected as a benefit of OLT in these patients. Growth failure as a primary indication for OLT should be cautiously examined in patients with AGS.
Collapse
Affiliation(s)
- R E Quiros-Tejeira
- Division of Pediatric Gastroenterology and Nutrition, University of California at Los Angeles Medical Center, 90095-1752, USA
| | | | | | | | | | | | | | | |
Collapse
|
17
|
Younes BS, McDiarmid SV, Martin MG, Vargas JH, Goss JA, Busuttil RW, Ament ME. The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients. Transplantation 2000; 70:94-9. [PMID: 10919581] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/17/2023]
Abstract
BACKGROUND Posttransplant lymphoproliferative disease (PTLD) is a serious complication associated with the use of chronic immunosuppression for solid organ transplantation. This study represents a retrospective analysis of UCLA's experience with PTLD in all pediatric liver transplant recipients between 1984-1997. We assessed the clinical presentation, risk factors, incidence density, immunological characteristics, management, and outcome of patients who developed PTLD when receiving either primary cyclosporin A (CsA) or tacrolimus. METHODS A total of 251 children received primary CsA therapy of which 70 required OKT3 for steroid resistant rejection and 29 required tacrolimus rescue for OKT3 resistance and/or chronic rejection. One hundred forty one children received tacrolimus as primary therapy. Sixty patients who survived for less than 6 months after transplantation were excluded from the study. RESULTS The total incidence density (ID) rate of PTLD was 1.8+/-0.4 per 100 patient-years (30/392). The overall ID rate of PTLD in the CsA group was 0.93+/-0.2 per 100 patient-years (15/251). Within this group of primary CsA-treated patients, the ID rate of PTLD was 0.49+/-0.1 without OKT3 or tacrolimus, 0.67+/-0.2 with OKT3, and 6.42+/-1.1 with tacrolimus rescue. The overall PTLD ID rate in the primary tacrolimus-treated patients was 4.86+/-1.2 per 100 person-years (15/141). There was a 5-fold increase in the ID rate of PTLD in the primary tacrolimus group when compared to the comparable, primary CsA group (P<0.001). The mean time to PTLD was 5-fold longer (49.7+/-20.7 months) in the CsA group when compared to the CsA/tacrolimus rescue group (9.8+/-3 months, P<0.05) or the tacrolimus primary group (12.6+/-5.1 months, P<0.05). Five patients had monoclonal disease in the CsA group, but only one in the tacrolimus group (P<0.05). Clinical presentations with enlarged lymph nodes, fevers, malaise, anorexia, weight loss, hypoalbuminemia, and gastrointestinal blood loss were common. Mortality was 20%, three patients died in each group. CONCLUSION The use of primary tacrolimus therapy was associated with a significant 5-fold higher rate of PTLD when compared to those treated with primary cyclosporine. Early diagnosis, decrease and/or discontinuation of potent immunosuppressive agents may contribute to decrease morbidity and mortality of this entity.
Collapse
Affiliation(s)
- B S Younes
- Division of Pediatric Gastroenterology and Nutrition UCLA Medical Center, Los Angeles, CA 90024-1752, USA
| | | | | | | | | | | | | |
Collapse
|
18
|
Quiros-Tejeira RE, Ament ME, Heyman MB, Martin MG, Rosenthal P, Hall TR, McDiarmid SV, Vargas JH. Variable morbidity in alagille syndrome: a review of 43 cases. J Pediatr Gastroenterol Nutr 1999; 29:431-7. [PMID: 10512403 DOI: 10.1097/00005176-199910000-00011] [Citation(s) in RCA: 83] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
BACKGROUND Alagille syndrome is one of the most common inherited disorders that cause chronic liver disease in children. Early reports suggested a benign course in these patients. Subsequent reports showed significant morbidity and mortality. This study was designed to analyze the long-term clinical course in Alagille syndrome. METHODS The records of children with Alagille syndrome seen during a 20-year period were reviewed. RESULTS Forty-three patients were identified. Liver disease was diagnosed before 12 months of age in 95%. The frequencies of renal anomalies (50%) and intracranial hemorrhage (12%) were significant. The high incidence of chronic otitis media (35%) has not been reported previously. One patient had a renal transplant. Vascular compromise as a pathologic mechanism for some characteristics of the syndrome is also suggested by the presence of small bowel stenosis and atresia, tracheal and bronchial stenosis, renal artery stenosis, middle aortic syndrome, and avascular necrosis of the humeral and femoral heads. Twenty (47%) patients underwent liver transplantation. Five of six who underwent Kasai procedure required liver transplantation. Twelve died (28%), five after liver transplantation. One patient died of intracranial bleeding. Sixteen (37%) without liver transplantation and 15 (35%) who underwent liver transplantation are alive. CONCLUSIONS Some patients with early-onset and more severe liver disease can benefit from liver transplantation. Careful and complete assessment should be made of infants with a cholestatic syndrome, to avoid misdiagnosis and unnecessary Kasai procedures. Our observation of vascular compromise in various organ systems suggests that notch signaling pathway defects affect angiogenesis in Alagille syndrome.
Collapse
Affiliation(s)
- R E Quiros-Tejeira
- Division of Pediatric Gastroenterology, University of California Los Angeles Medical Center 90095-1752, USA
| | | | | | | | | | | | | | | |
Collapse
|
19
|
Younes BS, Ament ME, McDiarmid SV, Martin MG, Vargas JH. The involvement of the gastrointestinal tract in posttransplant lymphoproliferative disease in pediatric liver transplantation. J Pediatr Gastroenterol Nutr 1999; 28:380-5. [PMID: 10204501 DOI: 10.1097/00005176-199904000-00007] [Citation(s) in RCA: 46] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/10/2022]
Abstract
BACKGROUND Posttransplant lymphoproliferative disease (PTLD) is a serious complication associated with the use of immunosuppression after transplantation. In a retrospective study the clinical features of PTLD located primarily in the gastrointestinal tract were analyzed. METHODS Three hundred ninety-two consecutive pediatric patients who underwent orthotopic liver transplantation (OLT) during a 13-year period with a survival of more than 6 months were reviewed. Two immunosuppression protocols were used: cyclosporin A, or tacrolimus-based primary therapy. Twenty-nine randomly selected liver transplant recipients without PTLD were used for comparison of signs and symptoms of gastrointestinal PTLD. RESULTS Among the 30 patients identified with PTLD, 9 had gastrointestinal PTLD. The overall incidence density of PTLD was 1.8 per 100 patient-years (30/392). Nine patients (30%) had involvement of the gastrointestinal tract, whereas 7 (23%) had the gastrointestinal tract as the only involved site. When compared with a cohort of liver transplant recipients without PTLD, only gastrointestinal bleeding, weight loss, hypoalbuminemia, and protein-losing enteropathy were signs most likely associated with gastrointestinal PTLD. Hypoalbuminemia was the most sensitive sign of gastrointestinal PTLD. The lower tract (ileum and colon) was the most common site of involvement. CONCLUSIONS gastrointestinal involvement is common and occurs in 30% of all patients with PTLD. It may be the only affected organ in a subgroup of patients. Hypoalbuminemia, gastrointestinal bleeding, and weight loss are features that are characteristic of gastrointestinal PTLD. Patients with aggressive gastrointestinal signs and symptoms should undergo upper and lower gastrointestinal tract endoscopy with biopsy, to establish the diagnosis.
Collapse
Affiliation(s)
- B S Younes
- Department of Pediatrics, University of California, Los Angeles, USA
| | | | | | | | | |
Collapse
|
20
|
Abstract
BACKGROUND We describe the incidence, results of interferon therapy, and outcome of hepatitis C virus (HCV) hepatitis occurring de novo after pediatric orthotopic liver transplantation (OLT). METHODS AND RESULTS Of children undergoing OLT between 1984 and September 1996, 321 children survived for more than 1 year. Of these, 13 (4.0%) developed previously undiagnosed HCV disease, as suggested by HCV antibody testing and HCV polymerase chain reaction and confirmed by liver biopsy. Of the 117 children who received transplants before HCV screening of blood products or donors, 10.2% developed de novo HCV disease. The mean age at diagnosis of HCV hepatitis was 13.2+/-5.0 years, and the mean time to diagnosis after OLT was 8.1 years (range, 4-11 years). The mean alanine aminotransferase (ALT) level at diagnosis was 108 IU/ml, and the liver biopsy specimen showed chronic active or chronic persistent hepatitis in 11 children, cirrhosis in 1 child, and nonspecific changes in 1 child. Twelve children were treated with interferon-2alpha; children who weighed > or =20 kg received 3 x 10(6) units every other day, and those who weighed <20 kg received 1.5 x 10(6) units every other day. Four patients developed rapidly progressive liver failure while receiving interferon therapy and required urgent re-transplantation. Three of the four children again developed histologic evidence of recurrent HCV 4-6 months after the second OLT, and all three subsequently died of HCV-induced liver failure. One patient remains alive and well with no evidence of HCV recurrence and a negative HCV RNA. Of the remaining eight children treated with interferon, only two have had a sustained response (normal ALT) and one is now HCV RNA negative. HCV RNA levels did not correlate with outcome or disease severity. HCV antibody levels were unreliable, with two patients having negative HCV antibody but a positive HCV RNA at diagnosis. Six patients were able to be genotyped: four were la and two were 1b. CONCLUSION Overall mortality for de novo HCV hepatitis was 23%. Seventy-five percent of children who received a second transplant for HCV hepatitis had early histologic recurrence that led to liver failure and death. Interferon therapy resulted in a sustained improvement in ALT in only 15% of children. The time to onset and progression of clinical disease both in the original graft and the retransplant graft were accelerated compared with nonimmunosuppressed individuals.
Collapse
Affiliation(s)
- S V McDiarmid
- Division of Pediatrics, Gastroenterology and Nutrition, UCLA Medical Center, Los Angeles, California 90095-1752, USA
| | | | | | | | | | | | | |
Collapse
|
21
|
Abstract
We have treated five patients with metatarsalgia and triggering of the lesser toes. This paper describes a mechanism of triggering that involves a previously undescribed flexor pulley system in the toes that is very similar to the pulley system in the fingers. The specific anatomy of the toe flexor pulleys is described based upon the dissections of 50 fresh-frozen cadaver toes. These pulleys were composed of transverse to obliquely oriented fibrous bands within the flexor sheaths from the metatarsal heads to the distal phalanges. We found a system of pulleys in the lesser toes and the great toe, analogous to that found in the hand. Trigger toe is a rare entity and is only briefly described in the literature. We believe it is more common than is now recognized and may be an important underdiagnosed cause of metatarsalgia. The diagnosis is made when active plantarflexion causes the toes to catch in flexion and the patient is then unable to extend them. Nonsurgical therapy consisting of steroid injection, NSAIDs, or changing footwear may be effective, otherwise surgical release of the A1 pulley may be required.
Collapse
Affiliation(s)
- M G Martin
- University Hospital, Birmingham, Alabama 35294-3295, USA
| | | |
Collapse
|
22
|
Hinrichs K, Martin MG, Schmidt AL, Friedman PP. Effect of follicular components on meiotic arrest and resumption in horse oocytes. J Reprod Fertil 1995; 104:149-56. [PMID: 7636796 DOI: 10.1530/jrf.0.1040149] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
Two experiments were conducted to evaluate the effect of follicular components on the maintenance of meiotic arrest in horse oocytes. In Expt 1, oocytes were incubated for 24 h with follicular fluid, or with granulosa cells suspended either in medium or in follicular fluid at 25 x 10(6) cells ml-1. None of the treatments resulted in significant maintenance of the germinal vesicle stage over that of non-suppressive control. Culture with follicular fluid plus granulosa cells resulted in a significantly higher proportion of oocytes at metaphase I compared with controls. In Expt 2, oocytes were divided into those originally having compact or expanded cumuli. Oocytes were cultured with sheets of mural granulosa or sections of follicle wall, or after injection into intact dissected follicles. After incubation, half of the oocytes from each suppressive treatment were matured for 24 h. All three suppressive treatments were effective in maintaining oocytes at the germinal vesicle stage (no significant difference from control oocytes fixed directly after removal from the follicle). However, no treatment maintained normal viability of oocytes, as significantly fewer oocytes were at metaphase II after all the suppression-maturation treatments compared with the maturation control. The highest rate of post-suppression maturation was found in the mural granulosa treatment. Within this treatment, the proportion of oocytes in metaphase II was significantly higher for oocytes with expanded than for oocytes with compact cumuli (31% versus 11%, respectively; P < 0.05). Suppression by injection into an intact follicle was associated with a lack of progression to metaphase II during subsequent maturation.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- K Hinrichs
- Tufts University School of Veterinary Medicine, North Grafton, MA 01536, USA
| | | | | | | |
Collapse
|
23
|
Hinrichs K, Schmidt AL, Friedman PP, Selgrath JP, Martin MG. In vitro maturation of horse oocytes: characterization of chromatin configuration using fluorescence microscopy. Biol Reprod 1993; 48:363-70. [PMID: 8439626 DOI: 10.1095/biolreprod48.2.363] [Citation(s) in RCA: 117] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023] Open
Abstract
The chromatin configuration of resting horse oocytes and the time course of in vitro oocyte maturation was characterized using a fluorescent, DNA-specific label. Oocytes were classified as having either compact (CP) or expanded (EX) cumuli at the time of collection. Centrifugation of oocytes was effective in allowing visualization of the germinal vesicle. Two main chromatin configurations were found in oocytes known to have a germinal vesicle: condensed chromatin (CC), in which the chromatin formed a dense mass surrounding the nucleolus; and fluorescing nucleus (FN), in which the entire nucleus, containing diffuse or spotty chromatin, was visible. The proportion of CC to FN was higher for oocytes with EX cumuli. At time 0, 78% of CP oocytes and 73% of EX oocytes were in the germinal vesicle stage. Significantly more EX than CP oocytes were in metaphase I or II at time 0. In both CP and EX groups, maturation had not begun after 8 h of incubation. Maximal maturation occurred after 24 h for oocytes in the EX group, whereas CP oocytes continued to mature between 24 and 32 h. The percentage of EX oocytes in metaphase I did not change between 24 and 32 h, indicating a possible arrest of some EX oocytes at metaphase I. There was no difference in the percentage of oocytes at metaphase II between the CP and EX groups after 32 h of incubation.
Collapse
Affiliation(s)
- K Hinrichs
- Department of Medicine, Tufts University School of Veterinary Medicine North Grafton, Massachusetts 01536
| | | | | | | | | |
Collapse
|
24
|
Karnes WE, Walsh JH, Wu SV, Kim RS, Martin MG, Wong HC, Mendelsohn J, Park JG, Cuttitta F. Autonomous proliferation of colon cancer cells that coexpress transforming growth factor alpha and its receptor. Variable effects of receptor-blocking antibody. Gastroenterology 1992; 102:474-85. [PMID: 1732118 DOI: 10.1016/0016-5085(92)90093-e] [Citation(s) in RCA: 56] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Four human colon adenocarcinoma cell lines, SNU-C1, SNU-C4, SNU-C5, and NCI-H716, that are capable of proliferating autonomously in serum-free medium containing no added peptide growth factors were identified. All four cell lines show epidermal growth factor (EGF) receptors (EGFRs), express transforming growth factor alpha (TGF-alpha) messenger RNA, and release anti-TGF-alpha-immunoreactive molecules. The blocking anti-EGFR monoclonal antibody (mAb) 225 blocks autonomous proliferation of SNU-C1 and SNU-C4 cells. In both of these cell lines, the inhibitory effect of mAb 225 is reversible by the addition of EGF, TGF-alpha, or conditioned medium from any of the four cell lines. In contrast, autonomous proliferation of SNU-C5 and NCI-H716 cells is not inhibited by mAb 225 and is not affected by exogenous EGF, TGF-alpha, or conditioned medium. Together, these data confirm the previous finding that anti-EGFR antibodies can inhibit the proliferation of some carcinoma cell lines that coexpress TGF-alpha and EGFR. However, here it is shown that the mechanisms of autonomous proliferation of colon carcinoma cell lines are heterogeneous and not always sensitive to antibody disruption of TGF-alpha/EGFR autocrine interactions.
Collapse
Affiliation(s)
- W E Karnes
- Center for Ulcer Research and Education, VA Wadsworth/UCLA
| | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Veiga FG, Varela JR, Chantada V, Martin MG. Coincidental renal angiomyolipoma and urothelial carcinoma of the renal pelvis in the same kidney diagnosed by CT. Br J Urol 1990; 66:216-7. [PMID: 2390710 DOI: 10.1111/j.1464-410x.1990.tb14911.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Affiliation(s)
- F G Veiga
- Department of Urology, Juan Canalejo Hospital, La Coruña, Spain
| | | | | | | |
Collapse
|
26
|
Abstract
We used [3H]nitrendipine to characterize dihydropyridine sensitive calcium channels on cells isolated from neonatal (1 d) and weanling (11 wk) rabbit gastric fundic and antral smooth muscle. Incubating with and without nifedipine 20 microM, specific binding was 56 +/- 4% of total binding at 0.1 nM [3H]nitrendipine. Specific binding was saturable, reversible, achieved equilibrium by 10 min at 4 degrees C, and was linearly related to cell concentration. The affinity constant for [3H]nitrendipine was higher in weanling fundus (kd = 243 +/- 121 pM) versus antrum (kd = 771 +/- 190 pM), p less than 0.05. There were no age-related changes in affinity. In the antrum, the number of binding sites (Bmax) increased from 6,000 +/- 266/cell in neonates to 27,500 +/- 8,440/cell in weanlings (p less than 0.05). In the fundus Bmax was 7,750 +/- 2,100/cell in neonates, and there was no age-related change. To assess function, we compared isometric stress in full thickness muscle strips oriented to the circular layer. Bethanechol stimulated dose-dependent tonic contractions in the fundus and phasic contractions in the antrum. Maximal stress increased with age from 305 +/- 54 mN/cm2 to 1140 +/- 73 mN/cm2 (p less than 0.05) in the fundus and from 72 +/- 20 mN/cm2 to 154 +/- 30 mN/cm2 (p less than 0.05) in the antrum. Preincubation and incubation without calcium resulted in reversible inhibition of contraction at both ages. Nifedipine 10-microM inhibited 100% of bethanechol-stimulated contraction in the antrum, but only 25% in the fundus at both ages.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- P E Hyman
- Department of Pediatrics, Harbor-UCLA Medical Center, Torrance 90509
| | | | | | | | | |
Collapse
|
27
|
Abstract
300 patients have been studied by means of a fluorescence exfoliative urinary cytology procedure based on the fluorochromatic properties and the affinity of acridine orange for the nucleic acids. The patients were divided inot two groups: in the first group including 238 cases we tried to establish the correlation between the urinary cytological grade and the histological grade of malignancy on biopsy; the rate of accuracy was approximately 77% for low-grade and approximately 88% for the high-grade tumours. In the second group including 62 cases we studied the value of cytology in predicting recurrences; 38 and 66.6% of the cases with grades IV and V, respectively, developed recurrences thus confirming the necessity of cytologic controls in patients under conservative treatment. The overall rate of accurate cytological diagnosis with this staining method has reached 90%.
Collapse
|
28
|
Martin MG, Barrilero AE, Borruel JL, Martinez-pineiro JA. [The diagnosis and partial nephrectomy of angiomyolipomas (author's transl)]. J Urol Nephrol (Paris) 1975; 81:797-804. [PMID: 1219132] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Renal angiomyolipoma is not a malignant tumor, and it is therefore to be treated only conservatively. The difficulty in distinguishing it from carcinoma nearly always leads to total nephrectomy. The study of the selective renal arteriogram enables preoperative diagnosis of angiomyolipoma even when not associated with tuberous sclerosis, and a partial nephrectomy. The arteriographic signs are: aneurysmatic images of the main vessels the neoplastic vessels with a helicoid course or arranged as bunche of grapes, their frequent anastomoses, the slowness of bloodflow in the angiomatous vessels and finally the mosaic picture during the nephrographic phase.
Collapse
|
29
|
Shah CP, Bain HW, Martin MG. Poisoning and poison control centres in Canada. Can Med Assoc J 1975; 113:523-30. [PMID: 1156979 PMCID: PMC1956757] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
Poisoning is a major and increasing health problem in the Western world. In 1972 the 310 poison control centres in Canada reported 53 531 enquiries about poisoning, 40% in adults. In 1964 the numbers of hospital admissions and deaths due to poisoning in this country were 2446 and 38, respectively, but in 1972 the figures were 6263 and 319, respectively. Most of the hospitalizations and deaths were among adults. Of 100 Canadian poison control centres two thirds were staffed by "any nurse in the emergency room", most of whom had received no training to answer the phone enquiries. However, two thirds agreed a training program is needed. Only 6.7% of 223 parents surveyed stated they would call a poison control centre if their child had accidentally swallowed a large amount of a poisonous substance. Regionalization of centres, a training program for personnel answering telephone enquiries, the need for crisis intervention as part of poison control programs, and public education about poisoning and poison control centres are the new challenges facing those providing health services.
Collapse
|
30
|
|
31
|
Martinez-Pineiro JA, Martin MG, Lanz FA. [Surgical treatment of stenosis of the urethra. Study of 95 cases]. J Urol Nephrol (Paris) 1973; 79:823-37. [PMID: 4613867] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
|
32
|
Martin MG, Reese CB. Some aspects of the chemistry of N(1)- and N(6)-dimethylallyl derivatives of adenosine and adenine. J Chem Soc Perkin 1 1968; 14:1731-8. [PMID: 5691105 DOI: 10.1039/j39680001731] [Citation(s) in RCA: 24] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
|
33
|
Martin MG. The dietitian as a manager. Can Hosp 1967; 44:56. [PMID: 6043720] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
|